Estimating Contralateral Breast Cancer Risk
- 54 Downloads
Purpose of review
Accurate estimates of contralateral breast cancer (CBC) risk are necessary around the time a first breast cancer is diagnosed to aid surgical decision-making. This review will discuss the known risk factors for contralateral breast cancer (CBC) and present methods for calculating CBC risk that can be utilized when breast surgeons counsel patients.
In addition to the well-known factors that impact contralateral breast cancer risk, such as BRCA1/BRCA2 mutation carrier status and history of chest wall radiation, other factors that affect CBC risk are being better defined. Recent studies that take into account important covariates in contralateral breast cancer risk, such as BRCA1 and BRCA2 mutation carrier status, family history, and systemic treatment, are further improving estimates of contralateral risk. Recent studies show family history, especially of breast cancer in a young relative or of bilateral breast cancer, hormone receptor status, lobular histology, and breast density are important in accurately estimating contralateral breast cancer risk. The Manchester formula, a pen and paper calculation for contralateral breast cancer risk estimation, and CBCRisk, a recently developed online CBC risk calculator, are two tools now available to clinicians.
Despite a decreasing incidence of contralateral breast cancer over the last few decades, there has been a steady increase in the number of women undergoing contralateral prophylactic mastectomy (CPM). The reasons for this are multifactorial, but fear of a contralateral breast cancer and a tendency to overestimate the risk of a contralateral breast cancer are two factors. Therefore, a critical element in decision-making for women considering CPM is having an accurate estimate of contralateral breast cancer risk. Models for estimating contralateral breast cancer risk are not widely used, but are available.
KeywordsContralateral breast cancer Prophylactic mastectomy Risk estimation
Compliance with Ethical Standards
Conflict of Interest
The author has no conflicts of interest to declare.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (eds). New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute. NIH Publ. No. 05-5302. National Cancer Institute Bethesda, MD, 2006.Google Scholar
- 14.Rosenberg S, Tracy M, Meyer M. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among women with breast cancer: a cross-sectional survey. Ann Int Med. 2013;159(6):373–81. https://doi.org/10.7326/0003-4819-159-6-201309170-00003.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.• Jagsi R, Hawley ST, Griffith KA, Janz NK, Kurian AW, Ward KC, et al. Contralateral prophylactic mastectomy decisions in a population based sample of patients with early stage breast cancer. JAMA Surg. 2017;152(3):274–82. https://doi.org/10.1001/jamasurg.2016.4749. This study demonstrates surgeon recommendation regarding contralateral prophylactic mastectomy does impact surgical decision making. CrossRefPubMedPubMedCentralGoogle Scholar
- 18.•• Van den Broek AJ, van’t Veer LJ, Hooning MJ, et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers. J Clin Oncol. 2016;34(5):409–18. https://doi.org/10.1200/JCO.2015.62.3942. This study demonstrates that age is a strong factor for cumulative CBC risk in BRCA1/2 mutation carriers and is evidence that age-specific risk estimates should be used when counseling patients CrossRefPubMedGoogle Scholar
- 19.Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjær L, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013;31:433–9.CrossRefPubMedGoogle Scholar
- 22.Hafty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359(1471–77)Google Scholar
- 29.Hwang ES, Migliorretti DL, Ballard-Barbash R, Weaver DL, Kerlikowske K. Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ. Cancer Epidemiol Biomark Prev. 2007;16(12):2587–93. https://doi.org/10.1158/1055-9965.EPI-07-0458.CrossRefGoogle Scholar